InvestorsHub Logo
Followers 4
Posts 1194
Boards Moderated 0
Alias Born 10/03/2015

Re: NY1972 post# 73199

Monday, 07/16/2018 9:40:36 PM

Monday, July 16, 2018 9:40:36 PM

Post# of 108191
More evidence a diversed T cell army is needed for objective response.

Conversely,only 2 out of 18 tumors with a high subclonal neoantigen fraction (>5%) or low clonal neoantigen burden benefited from pembrolizumab (Y2087 and SB10944)
http://science.sciencemag.org/content/351/6280/1463.full
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News